ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Summary

The ENLIGHT-AML study is a Phase 1, open-label, dose-escalation and expansion study of GB3226 in the treatment of relapsed or refractory acute myeloid leukaemia

Timeline

Start

2026-06-10

Primary completion

2029-06-10

Completion

2029-10-10

Outcome

Outcome not reported

Stopped (Business): “Study withdrawn due to business priority changes”

Drugs

Indications